[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100603130":3},{"organization":4,"armGroups":7,"interventions":23,"overallOfficials":22,"centralContacts":28,"locations":38,"responsibleParty":57,"collaborators":22,"id":59,"slug":60,"hasResults":61,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":22,"eligibilityCriteria":65,"healthyVolunteers":61,"sex":66,"minAge":67,"maxAge":68,"enrollmentInfo":69,"targetDuration":22,"studyType":72,"phases":73,"briefSummary":75,"conditions":76,"keywords":22,"overallStatus":41,"whyStopped":22,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":89},{"fullName":5,"class":6},"Mansoura University","OTHER",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"Anticoagulant in cirrhosis with HCC","EXPERIMENTAL","HCC patient on anticogulant like Enoxaparin (clexan), warfarrin(marivan), or DOAC(apixaban)",[13],"Drug: Enoxaparin, warfarrin, or apixaban",{"label":15,"type":10,"description":16,"interventionNames":17},"Anticoagulant in Cirrhosis without HCC","Benign thrombus in cirrhotic patient on anticoagulant like Enoxaparin (clexan), warfarrin(marivan), or DOAC(apixaban)",[13],{"label":19,"type":20,"description":21,"interventionNames":22},"No anticoagualnt in Cirrhosis with or without HCC","NO_INTERVENTION","cirrhotic patients with thrombosis with or without HCC not on anticoagulant",null,[24],{"type":25,"name":26,"description":26,"armGroupLabels":27,"otherNames":22},"DRUG","Enoxaparin, warfarrin, or apixaban",[15,9],[29,34],{"name":30,"role":31,"phone":32,"phoneExt":22,"email":33},"Dalia Elsayed Ganady, MBBS","CONTACT","+201095529264","dalia.tawfik97@gmail.com",{"name":35,"role":31,"phone":36,"phoneExt":22,"email":37},"Hatem Elalfy, PhD","+201224790518","elalfy2004@mans.edu.eg",[39],{"facility":40,"status":41,"city":42,"state":43,"zip":44,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"Mansoura University Hospitals","RECRUITING","Al Mansurah","Dakahlia Governorate","35511","Egypt","EG",{"type":48,"coordinates":49},"Point",[50,51],31.38069,31.03637,{"lat":51,"lon":50},[54],{"name":55,"role":31,"phone":56,"phoneExt":22,"email":33},"Dalia E Tawfik","+20 1095529264",{"type":58,"investigatorFullName":22,"investigatorTitle":22,"investigatorAffiliation":22,"oldNameTitle":22,"oldOrganization":22},"SPONSOR","100603130","phase-4-efficacy--safety-of-anticoagulants-in-cirrhosis--hcc-100603130",false,"NCT07132515","Efficacy & Safety of Anticoagulants in Cirrhosis ± HCC","Efficacy and Safety of Anticoagulant Therapy for Portal Vein Thrombosis In Cirrhosis Patients With and Without Hepatocellular Carcinoma","Inclusion Criteria:\n\n* Portal vein thrombosis, Cirrhosis, With or without HCC, Child A \\& B\n\nExclusion Criteria:\n\n* Platelets\\\u003C10000, Createnine \\>1.9, Budd ciarri, Uncontrolled active bleeding","ALL","18 Years","70 Years",{"count":70,"type":71},100,"ESTIMATED","INTERVENTIONAL",[74],"PHASE4","We will give an anticoagulant against portal vein thrombosis, and watch for the results.",[77,78,79],"Cirrhosis","HCC - Hepatocellular Carcinoma","Portal Vein Thrombosis","2025-08-17",{"date":82,"type":83},"2025-08-20","ACTUAL",{"date":85,"type":83},"2023-08-15",{"date":87,"type":71},"2025-08",{"name":5,"class":6},1]